linjc16/ctgov huggingface dataset:
Prone Positioning for Brain-injured Patients With Severe ARDS (ProBrain)

Study Overview
=================
Brief Summary
-----------------
Prone position (PP) is a key component to treat hypoxemia in patients with severe acute respiratory distress syndrome (ARDS). However, most studies evaluating PP effects in patients with ARDS exclude those with brain-injuries without providing any medical evidence. This prospectice observational study aimed to investigate if prone positioning leads to significant modification of cerebral perfusion in brain-injured patients with ARDS.

Official Title
-----------------
Prone Positioning for Brain-injured Patients With Severe ARDS (ProBrain)

Conditions
-----------------
Cerebral Blood Flow

Intervention / Treatment
-----------------
* Other: Transcranial Doppler (TCD)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult's patients suffering from brain injuries patients neurologically monitored with TCD patients requiring prone position for severe ARDS Exclusion Criteria: pregnant women patients with contrindication to prone position

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years


Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Transcranial Doppler (TCD)|TCD ultrasonography is based on the principle of the Doppler effect. According to this principle, ultrasound waves emitted from the Doppler probe are transmitted through the skull and reflected by moving red blood cells within the intracerebral vessels. The difference in the frequency between the emitted and reflected waves, referred to as the Doppler shift frequency, is directly proportional to the speed of the moving red blood cells (blood flow). Cerebral blood flow (in cm/s) of the middle cerebral artery will be measured with TCD in blood-injured ARDS patients before and one hour after prone positioning (normal ranges: 48 to 72 cm/s).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral Blood Flow | Cerebral Blood Flow measurement before and after prone positioning | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Respiratory Distress Syndrome, Prone Position, Intracranial Pressure
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to evaluate the effect of study drug known as LY3209590 compared to insulin glargine administered in participants with type 2 diabetes mellitus (T2DM). Side effects and tolerability will be documented. The study will last almost six months and 21 visits for each participant including screening period.

Official Title
-----------------
Effects of LY3209590 on Frequency and Severity of Hypoglycaemia Under Conditions of Increased Hypoglycaemic Risk Compared to Insulin Glargine in Participants With Type 2 Diabetes Mellitus

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Insulin Glargine
* Drug: LY3209590


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 1 year prior to screening Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²) Be treated for T2DM with stable dose of metformin, a stable dose of a dipeptidyl peptidase-4 (DPP-4) inhibitor with or without metformin, or a stable dose of a glucagon-like peptide-1 (GLP-1) receptor agonist with or without metformin for at least 3 months prior to screening Exclusion Criteria: Have an abnormality in the 12-lead ECG Have a supine blood pressure at screening Have alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5x upper limit of normal (ULN) Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (except T2DM and controlled thyroid disease), haematological, or neurological disorders Are receiving chronic (lasting longer than 14 consecutive days) systemic or inhaled glucocorticoid therapy Have an average weekly alcohol intake

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Insulin Glargine (Period 1)<br>Insulin glargine administered subcutaneously (SC). | Drug: Insulin Glargine<br>* Administered SC<br>|
| Experimental: LY3209590 (Period 2)<br>LY3209590 administered SC. | Drug: LY3209590<br>* Administered SC<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Documented Hypoglycemia | Incidence of Documented Hypoglycemia | Baseline through Day 186 |
Effect of Duration of Exposure of Anesthesia With Sevoflurane on Emergence Delirium

Study Overview
=================
Brief Summary
-----------------
Emergence delirium which is a phenomenon seen commonly in preschool kids anesthetized with Sevoflurane. Restless recovery from anesthesia may not only cause injury to the child or to the surgical site, but may also lead to the accidental removal of surgical dressings, IV catheters, and drains. is one of the The purpose of the study is to find whether duration of exposure to Sevoflurane has any effect on the incidence of Emergence Delirium.

Conditions
-----------------
Delirium on Emergence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 1-6 years of age receiving general anesthesia for non-surgical procedure Exclusion Criteria: history of emergence delirium severe CNS disease

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Less than 30 minutes<br> | |
| 30-60 minutes<br> | |
| More than 60 minutes<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of emergence delirium | using the PAED scale | 30 mintes after anesthesia | 
| Severity of emergence delirium | using the PAED scale | 30 minutes after anesthesia |
Endocervical Lidocaine Spray for Pain Control During Office Hysteroscopy

Study Overview
=================
Brief Summary
-----------------
lidocaine spray is used endocervical before office hysteroscopy to reduce the pain

Detailed Description
-----------------
5 sprays of Lidocaine is applied 3 minutes before office hysteroscopy

Official Title
-----------------
Endocervical Lidocaine Spray for Pain Control During Office Hysteroscopy - a Randomized Control Trial.

Conditions
-----------------
Pain Uterus

Intervention / Treatment
-----------------
* Drug: Endocervical Lidocaine spray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients indicated for diagnostic hysteroscopy for infertility or AUB. Postmenstrual between days 7 and 11 of the cycle ( except in irregular bleeding) Exclusion Criteria: Contraindication to office hysteroscopy Neurological disorders affecting the evaluation of pain. Previous cervical surgery.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized controlled trial
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group A (Lidocaine group)<br>5 sprays of endocervical Lidocaine 10% spray ( AstraZeneca, bedforshire) are used 3 minutes before office hysteroscopy | Drug: Endocervical Lidocaine spray<br>* 5 sprays of endocervical Lidocaine spray (10%) is used 3 minutes before office hysteroscopy<br>|
| No Intervention: Group B (control group)<br>office hysteroscopy is done without analgesia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain sensation | The level of pelvic pain will be rated according to a 10-point visual analogue scale (VAS) | The VAS will be applied immediately after the procedure ended | 
| Procedure time | from introduction of the office hysteroscopy through the external cervical os and the visualization of the uterine cavity | immediately after the process | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
office hysteroscopy, Lidocaine spray
Near Horizontal Heterophoria in Chinese Children

Study Overview
=================
Brief Summary
-----------------
This study aimed to assess the association of refraction and axial length with near-horizontal heterophoria in a large population-based study of school-aged Chinese children. The study makes a significant contribution to better know the etiology of myopia progression and ocular axial length development. Further, this study will be of interest to the readership of your journal because its noteworthy finding and which could contribute to guide recommendations for targeted interventions to slow myopia progression.

Detailed Description
-----------------
Myopia is becoming a global public health burden which is believed to have a multifactorial etiology. The relationship between heterophoria and refraction remains controversial. We describe the association of refraction and axial length (AL) with heterophoria in a large population-based study of school-aged Chinese children. Eleven thousand thirteen elementary school children grades 1-6, were included in this school-based, cross-sectional study. Near phoria data was quantified by using Maddox rod test and prism at 33 cm. Children in each grade level were sorted into three groups based upon phoria: 1) those with more than six prism diopters (PD) exophoria, 2) those with zero to six PD exophoria, and 3) those with any amount of esophoria. Autorefraction was measured by autorefractor (Topcon KR8900, Japan) and AL was measured by Optical Biometer AL-Scan (Nidek AL-Scan, Japan). A generalized additive model (GAM) was applied with a Gaussian link to explore the association between the refractive error or axial length and heterophoria. An additional age-adjusted model was also employed for analysis.

Official Title
-----------------
Association of Axial Length and Refraction With Near Horizontal Heterophoria in Chinese Children

Conditions
-----------------
Myopia, Progressive

Intervention / Treatment
-----------------
* Other: axial length and refractive error


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages of 6 and 13 years Chinese school children Exclusion Criteria: Subjects with eye diseases or strabismus

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| zero to six Exo<br> | Other: axial length and refractive error<br>* Comparing the correlation between heterophoria and refraction, even after age adjustment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| refractive error |  | change from baseline with EDTRS chart at 6 months |
Safety Study of Viaskin Peanut to Treat Peanut Allergy

Study Overview
=================
Brief Summary
-----------------
This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment.

Conditions
-----------------
Peanut Allergy

Intervention / Treatment
-----------------
* Biological: Viaskin Peanut 250 mcg
* Biological: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physician-diagnosed peanut allergy; A peanut Skin Prick Test (SPT) with a wheal largest diameter ≥8 mm; A specific-peanut Immunoglobulin E (IgE) ≥14 kU/L; Subjects following a strict peanut-free diet. Exclusion Criteria: Generalized dermatologic disease Spirometry forced expiratory volume in 1 second (FEV1) <80% of the predicted value, or peak expiratory flow (PEF) <80% of predicted value; Receiving β-blocking agents, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium channel blockers or tricyclic antidepressant therapy; anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) or any biologic immunomodulatory therapy; Prior or concomitant history of any immunotherapy to any food allergy (for example EPIT, OIT, SLIT, or specific oral tolerance induction).

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Viaskin Peanut 250 mcg<br>Viaskin Peanut 250 mcg, daily administration | Biological: Viaskin Peanut 250 mcg<br> <br> |
| Placebo Comparator: Placebo<br>Placebo patch, daily administration | Biological: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) |  | Through study completion, an average of 3 years |
Postoperative Residual Paralysis After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to describe the incidence of postoperative residual paralysis (mean train-of-four <90%) when weaning from the ventilator in patients admitted to the Intensive Care Unit (ICU) after elective cardiac surgery. Train-of-four monitoring is a widely used term for the peripheral nerve stimulation used in neuromuscular blockade monitoring. When the patient is ready for weaning from the ventilator, an ICU doctor will perform a measurement of the train-of-four at the thumb with a neuromuscular transmission monitor. Every value below 90% will be considered as residual paralysis and treated appropriately by means of a reversal agent.

Detailed Description
-----------------
Postoperatively, in the ICU, readiness-for-weaning is based on ICU doctor-nurse-driven institutional weaning guidelines: 6 hours after arrival in the ICU, a patient who is normothermic, hemodynamically stable, has normal blood gasses and absence of residual bleeding. The ICU nurse caring for the patient will start weaning the patient from the ventilator, following these departmental guidelines.

Official Title
-----------------
Is Postoperative Residual Curarisation Still an Issue at the Moment of Weaning of the ICU Patient Following Cardiac Surgery?

Conditions
-----------------
Postoperative Residual Curarization

Intervention / Treatment
-----------------
* Device: peripheral neuromuscular monitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients admitted to the ICU after elective cardiac surgery Exclusion Criteria: emergency cardiac surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: Patients admitted to the ICU after elective cardiac surgery and ready for weaning from the ventilator.
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: peripheral neuromuscular monitor|Residual paralysis can only be measured by neuromuscular transmission monitoring of a peripheral nerve, typically the ulnar nerve innervating the adductor pollicis muscle.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative residual curarisation | mean train-of-four <90% as measured by neuromuscular blockade monitoring | 6 hours after arrival in the ICU | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neuromuscular blockade, neuromuscular monitoring
Compliance of Traditional Chinese Medicine in Young Patients With Rheumatic Diseases

Study Overview
=================
Brief Summary
-----------------
To evaluate the compliance of traditional Chinese medicine (TCM) in young people with Chronic rheumatic disease

Conditions
-----------------
Chronic Rheumatic Diseases

Intervention / Treatment
-----------------
* Other: patient-tailored anti-arthritis herbs
* Other: patient-tailored DMARDs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: were between 18 and 35 years of age without use of TCM in the previous 3 months and had a Steinbrocker functional status of class I, II, or III Exclusion Criteria: previous general health conditions disallowed their use of TCM were pregnant lack of motivation, remote from home, time-consuming,intervention, or other personal difficulties

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patient-tailored anti-arthritis herbs<br>patient use tailored anti-arthritis herbs | Other: patient-tailored anti-arthritis herbs<br>* patient use tailored anti-arthritis herbs<br>|
| Active Comparator: patient-tailored DMARDs<br>Patients use tailored DMARDs | Other: patient-tailored DMARDs<br>* patient use tailored disease-modifying antirheumatic drugs<br>* Other names: patient-tailored disease-modifying antirheumatic drugs;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline in HBCS(Hill-Bone Compliance Scale) score at 48 weeks |  | at 0 week, 12 weeks, 24 weeks, 48 weeks | 
| Changes from baseline in MARS(Medication Adherence Rating Scale) score at 48 weeks |  | at 0 week, 12 weeks, 24 weeks, 48 weeks |
Microenvironment of Adipose Tissue in Endocannabinoid System

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is examine the relationship between adipose tissue inflammation and activation of the endocannabinoid system before and after Roux-en-Y gastric bypass surgery. The investigators hypothesize that the metabolic improvements and weight loss are due to mechanisms that antagonize the endocannabinoid system.

Official Title
-----------------
Microenvironment of Adipose Tissue in Endocannabinoid System Before and After Roux-en-y Gastric Bypass Surgery

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI>35 kg/m2 Age 20-60 yrs Approved and scheduled for gastric bypass surgery Stable body weight for past 3 months Exclusion Criteria: Positive pregnancy test Previous gastric surgeries Intercurrent infections History of ketoacidosis or current metabolic acidosis Serum creatinine or liver function tests > 2 times upper limits of normal Taking drugs that are known to affect carbohydrate or lipid metabolism other than anti-diabetes mediations.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, gastric bypass surgery